AWM Investment Company Inc. bought a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 80,000 shares of the company's stock, valued at approximately $2,111,000. AWM Investment Company Inc. owned approximately 0.23% of Alto Neuroscience as of its most recent filing with the SEC.
A number of other hedge funds also recently modified their holdings of ANRO. Torren Management LLC bought a new position in shares of Alto Neuroscience in the 4th quarter valued at $62,000. GK Wealth Management LLC acquired a new position in shares of Alto Neuroscience during the 2nd quarter worth $226,000. Balyasny Asset Management L.P. bought a new stake in shares of Alto Neuroscience during the 4th quarter worth $198,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Alto Neuroscience during the 4th quarter worth $221,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Alto Neuroscience in the fourth quarter valued at about $304,000.
Analysts Set New Price Targets
ANRO has been the subject of several research reports. Wolfe Research started coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They issued an "outperform" rating for the company. Wedbush upped their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Thursday, August 13th. Zacks Research upgraded Alto Neuroscience from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Finally, HC Wainwright raised their price objective on Alto Neuroscience from $50.00 to $55.00 and gave the company a "buy" rating in a report on Monday, August 17th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience presently has an average rating of "Moderate Buy" and an average price target of $37.25.
Check Out Our Latest Report on ANRO
Alto Neuroscience Price Performance
Alto Neuroscience stock opened at $36.20 on Wednesday. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -14.96 and a beta of 1.06. Alto Neuroscience, Inc. has a 52-week low of $3.41 and a 52-week high of $37.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The stock's 50 day moving average price is $27.97 and its two-hundred day moving average price is $23.74.
Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.08. On average, equities analysts predict that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current year.
Alto Neuroscience Profile
(
Free Report)
Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.
See Also
Want to see what other hedge funds are holding ANRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alto Neuroscience, Inc. (NYSE:ANRO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
